A new high-resolution neural recording method developed by Johns Hopkins APL and the School of Medicine detects neural ...

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Researchers have explored how a particular chemical can selectively trap certain molecules in the cavities of its ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated ...

--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical ... those without the biomarker. Alto does not currently intend to advance ALTO-100 in MDD. ALTO-100 is currently being ...

Both Big Pharma Sanofi and AI-focused biotech Formation Bio plan on using Muse in upcoming clinical ... expected for phase 3 ...

Researchers successfully tested the safety and preliminary efficacy of stem-cell-derived corneal implants, showing promise ...

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and <a target=_blank href= ...